New-generation efflux pump inhibitors

References

• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta455(1), 152–162 (1976).
   PubMed Web of Science ®Google Scholar
• Girardin F. Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin. Neurosci.8(3), 311–321 (2006).
   PubMedGoogle Scholar
• Majumdar S, Duvvuri S, Mitra AK. Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development. Adv. Drug Deliv. Rev.56(10), 1437–1452 (2004).
   PubMed Web of Science ®Google Scholar
• Varma MV, Perumal OP, Panchagnula R. Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery. Curr. Opin. Chem. Biol.10(4), 367–373 (2006).
   PubMed Web of Science ®Google Scholar
• Leveque D, Jehl F. P-glycoprotein and pharmacokinetics. Anticancer Res.15(2), 331–336 (1995).
   PubMed Web of Science ®Google Scholar
• Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol.25(4), 231–259 (2006).
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA84(21), 7735–7738 (1987).
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem.38(9), 1277–1287 (1990).
   PubMed Web of Science ®Google Scholar
• Tsuji A. P-glycoprotein-mediated efflux transport of anticancer drugs at the blood–brain barrier. Ther. Drug Monit.20(5), 588–590 (1998).
   PubMed Web of Science ®Google Scholar
• Goldberg H, Ling V, Wong PY, Skorecki K. Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem. Biophys. Res. Commun.152(2), 552–558 (1988).
   PubMed Web of Science ®Google Scholar
• Yang CP, DePinho SG, Greenberger LM, Arceci RJ, Horwitz SB. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J. Biol. Chem.264(2), 782–788 (1989).
   PubMed Web of Science ®Google Scholar
• Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res.49(18), 5002–5006 (1989).
   PubMed Web of Science ®Google Scholar
• Karlsson J, Kuo SM, Ziemniak J, Artursson P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol.110(3), 1009–1016 (1993).
   PubMed Web of Science ®Google Scholar
• de Lannoy IA, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem. Biophys. Res. Commun.189(1), 551–557 (1992).
   PubMed Web of Science ®Google Scholar
• Mazel M, Clair P, Rousselle C et al. Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs12(2), 107–116 (2001).
   PubMed Web of Science ®Google Scholar
• Raub TJ. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharm.3(1), 3–25 (2006).
   PubMed Web of Science ®Google Scholar
• Varma MV, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res.48(4), 347–359 (2003).
   PubMed Web of Science ®Google Scholar
• Woo JS, Lee CH, Shim CK, Hwang SJ. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm. Res.20(1), 24–30 (2003).
   PubMed Web of Science ®Google Scholar
• Banerjee SK, Jagannath C, Hunter RL, Dasgupta A. Bioavailability of tobramycin after oral delivery in FVB mice using CRL-1605 copolymer, an inhibitor of P-glycoprotein. Life Sci.67(16), 2011–2016 (2000).
   PubMed Web of Science ®Google Scholar
• Pardridge WM (Ed.). Introduction to the Blood–Brain Barrier. Methodology, Biology and Pathology. Cambridge University Press, UK (1998).
   Google Scholar
• Batrakova EV, Miller DW, Li S, Alakhov V, Kabanov AV, Elmquist WF. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J. Pharmacol. Exp. Ther.296(2), 551–557 (2001).
   PubMed Web of Science ®Google Scholar
• Malingre MM, Ten Bokkel Huinink WW, Mackay M, Schellens JH, Beijnen JH. Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel. Eur. J. Clin. Pharmacol.57(4), 305–307 (2001).
   PubMed Web of Science ®Google Scholar
• Leu BL, Huang JD. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother. Pharmacol.35(5), 432–436 (1995).
   PubMed Web of Science ®Google Scholar
• Floren LC, Bekersky I, Benet LZ et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin. Pharmacol. Ther.62(1), 41–49 (2001).
   Google Scholar
• Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet.42(13), 1141–1160 (2003).
   PubMed Web of Science ®Google Scholar
• Potschka H, Baltes S, Loscher W. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res.58(2–3), 85–91 (2004).
   PubMed Web of Science ®Google Scholar
• Olson DP, Scadden DT, D’Aquila RT, De Pasquale MP. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS16(13), 1743–1747 (2002).
   PubMed Web of Science ®Google Scholar
• Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm. Res.15(8), 1160–1167 (1998).
   PubMed Web of Science ®Google Scholar
• Seral C, Carryn S, Tulkens PM, Van Bambeke F. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. J. Antimicrob. Chemother.51(5), 1167–1173 (2003).
   PubMed Web of Science ®Google Scholar
• Wang S, Folkes A, Chuckowree I et al. Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance. J. Med. Chem.47(6), 1329–1338 (2004).
   PubMed Web of Science ®Google Scholar
• O’Connor R, Heenan M, Connolly L, Larkin A, Clynes M. Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res.24(2A), 457–464 (2004).
   PubMed Web of Science ®Google Scholar
• Hu K, Morris ME. Effects of benzyl-, phenethyl-, and a-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport. J. Pharm. Sci.93(7), 1901–1911 (2004).
   PubMed Web of Science ®Google Scholar
• Lehne G, Mørkrid L, den Boer M, Rugstad HE. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP). Int. J. Clin. Pharmacol. Ther.38(4), 187–195 (2000).
   PubMed Web of Science ®Google Scholar
• Friedenberg WR, Rue M, Blood EA et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer106(4), 830–838 (2006).
   PubMed Web of Science ®Google Scholar
• Sato W, Fukazawa N, Suzuki T, Yusa K, Tsuruo T. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res.51(9), 2420–2424 (1991).
   PubMed Web of Science ®Google Scholar
• Hyafil F, Vergely C, DuVignaud P, Grand-Perret T. in vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res.53(19), 4595–4602 (1993).
   PubMed Web of Science ®Google Scholar
• Planting AS, Sonneveld P, van der Gaast A et al. A Phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother. Pharmacol.55(1), 91–99 (2005).
   PubMed Web of Science ®Google Scholar
• Kuppens IE, Witteveen EO, Jewell RC et al. A Phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin. Cancer Res.13(11), 3276–3285 (2007).
   PubMed Web of Science ®Google Scholar
• Bardelmeijer HA, Beijnen JH, Brouwer KR et al. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res.6(11), 4416–4421 (2000).
   PubMed Web of Science ®Google Scholar
• Malingré MM, Beijnen JH, Rosing H et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br. J. Cancer84(1), 42–47 (2001).
   PubMed Web of Science ®Google Scholar
• Dantzig AH, Shepard RL, Law KL et al. J. Pharmacol. Exp. Ther.290(2), 854–862 (1999).
   PubMed Web of Science ®Google Scholar
• Rubin EH, de Alwis DP, Pouliquen I et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin. Cancer Res.8(12), 3710–3717 (2002).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gordon M, De Alwis DP et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin. Cancer Res.10(10), 3265–3272 (2004).
   PubMed Web of Science ®Google Scholar
• Gerrard G, Payne E, Baker RJ et al. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica89(7), 782–790 (2004).
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C. Phase I/II trial of a P-glycoprotein inhibitor, zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin’s lymphoma. Leuk. Lymphoma48(4), 708–715 (2007).
   PubMed Web of Science ®Google Scholar
• Fracasso PM, Goldstein LJ, de Alwis DP et al. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin. Cancer Res.10(21), 7220–7228 (2004).
   PubMed Web of Science ®Google Scholar
• Lê LH, Moore MJ, Siu LL et al. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother. Pharmacol.56(2), 154–160 (2005).
   PubMed Web of Science ®Google Scholar
• Bardelmeijer HA, Ouwehand M, Beijnen JH, Schellens JH, van Tellingen O. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest. New Drugs22(3), 219–229 (2004).
   PubMed Web of Science ®Google Scholar
• Wouters W, Jannssens F, van Dun J, Krekels M, Smets G. R101933 is an antagonist of Pgp and modulates resistance to different chemotherapy agents. Proc. Am. Assoc. Cancer Res.40, 4374 (1999).
   Google Scholar
• Van Ginckel R, Floren W, Moelans P, Jannssens B, Moelenberghs K, Wouters W. Oral treatment with R101933 restores the sensitivity towards paclitaxel and adriamycin in resistant human tumours xenografted in athymic mice. Proc. Am. Assoc. Cancer Res.40, 4375 (1990).
   Google Scholar
• van Zuylen L, Sparreboom A, van der Gaast A et al. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin. Cancer Res.6(4), 1365–1371 (2000).
   PubMed Web of Science ®Google Scholar
• Newman MJ, Rodarte JC, Benbatoul KD et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res.60(11), 2964–2972 (2000).
   PubMed Web of Science ®Google Scholar
• Kuppens IE, Bosch TM, van Maanen MJ et al. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother. Pharmacol.55(1), 72–78 (2005).
   PubMed Web of Science ®Google Scholar
• Chi KN, Chia SK, Dixon R et al. A Phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest. New Drugs23(4), 311–315 (2005).
   PubMed Web of Science ®Google Scholar
• Roe M, Folkes A, Ashworth P et al. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg. Med. Chem. Lett.9(4), 595–600 (1999).
   PubMed Web of Science ®Google Scholar
• Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin. Cancer Res.6(11), 4186–4191 (2000).
   PubMed Web of Science ®Google Scholar
• Werle M. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm. Res.25(3), 500–511 (2008).
   PubMed Web of Science ®Google Scholar
• Werle M. Polymeric and low molecular mass efflux pump inhibitors for oral drug delivery. J. Pharm. Sci.97(1), 60–70 (2008).
   PubMed Web of Science ®Google Scholar
• Johnson BM, Charman WN, Porter CJH. An in vitro examination of the impact of polyethtylene glycol 400, pluronic P 85 and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on P-Glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci.4(4), E40 (2002).
   PubMedGoogle Scholar
• Shen Q, Lin Y, Handa T et al. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int. J. Pharm.313(1–2), 49–56 (2006).
   PubMed Web of Science ®Google Scholar
• Hugger ED, Audus KL, Borchardt RT. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J. Pharm. Sci.91(9), 1980–1990 (2002).
   PubMed Web of Science ®Google Scholar
• Choi JS, Jo BW. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int. J. Pharm.280(1–2), 221–227 (2004).
   PubMed Web of Science ®Google Scholar
• Varma MV, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur. J. Pharm. Sci.25, 445–453 (2005).
   PubMed Web of Science ®Google Scholar
• Collnot EM, Baldes C, Wempe MF et al. Influence of vitamin E TPGS poly(ethlyene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J. Control. Release111, 35–40 (2006).
   PubMed Web of Science ®Google Scholar
• Friche E, Jensen PB, Sehested M, Demant EJ, Nissen NN. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun.2(9), 297–303 (1990).
   PubMed Web of Science ®Google Scholar
• Shono Y, Nishihara H, Matsuda Y et al. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J. Pharm. Sci.93(4), 877–885 (2004).
   PubMed Web of Science ®Google Scholar
• Lo YL. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J. Control. Release90(1), 37–48 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang H, Yao M, Morrison RA, Chong S. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch. Pharm. Res.26(9), 768–772 (2003).
   PubMed Web of Science ®Google Scholar
• Rege BD, Kao JP, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci.16(4–5), 237–246 (2002).
   PubMed Web of Science ®Google Scholar
• Liu C, Wu J, Shi B, Zhang Y, Gao T, Pei Y. Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate. Drug Dev. Ind. Pharm.32(1), 115–123 (2006).
   PubMed Web of Science ®Google Scholar
• Föger F, Hoyer H, Kafedjiiski K, Thaurer M, Bernkop-Schnürch A. in vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein. Biomaterials27(34), 5855–5860 (2006).
   PubMed Web of Science ®Google Scholar
• Hunter RL, McNicholl J, Lal AA. Mechanisms of action of nonionic block copolymer adjuvants. AIDS Res. Hum. Retroviruses10(2), 95–98 (1994).
   Google Scholar
• Rodeheaver G, Turnbull V, Edgerton MT, Kurtz L, Edlich RF. Pharmacokinetics of a new skin wound cleanser. Am. J. Surg.132(1), 67–74 (1976).
   PubMed Web of Science ®Google Scholar
• Alakhov V, Moskaleva EY, Batrakova EV, Kabanov AV. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug. Chem.7, 209–216 (1996).
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Vinogradov SV, Alakhov V, Miller DW, Kabanov AV. Mechanism of pluronic effect on P-glycoprotein efflux system in blood brain barrier: contributions of energy depletion and membrane fluidization. Pharmacol. Exp. Ther.299, 483–493 (2001).
   PubMed Web of Science ®Google Scholar
• Miller DW, Batrakova EV, Waltner DO, Alakhov V, Kabanov AV. Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence for two potential pathways for drug absorption. Bioconjug. Chem.8, 649–657 (1997).
   PubMed Web of Science ®Google Scholar
• Jagannath C, Wells A, Mshvildadze M et al. Significantly improved oral uptake of amikacin in FVB mice in the presence of CRL-1605 copolymer. Life Sci.64(19), 1733–1738 (1999).
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV, Miller DW. Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv. Drug Deliv. Rev.55, 151–164 (2003).
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Miller DW, Kabanov AV. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res.16(9), 1366–1372 (1999).
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev.54(5), 759–779 (2002).
   PubMed Web of Science ®Google Scholar
• Alakhov V, Klinksi E, Li S et al. Block co-polymer based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf. B Biointerfaces16, 113–134 (1999).
   Web of Science ®Google Scholar
• Venne A, Li S, Mandeville R, Kabanov AV, Alakhov V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res.56(16), 3626–3629 (1996).
   PubMed Web of Science ®Google Scholar
• Batrakova E, Lee S, Li S, Venne A, Alakhov V, Kabanov AV. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res.16(9), 1373–1379 (1999).
   PubMed Web of Science ®Google Scholar
• Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, Borst P. Inhibitory effect of the reversal agents V-104, GF120918 and pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br. J. Cancer83(3), 366–374 (2000).
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Han HY, Alakhov V, Miller DW, Kabanov AV. Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm. Res.15(6), 850–855 (1998).
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Li Y, Alakhov VY, Kabanov AV. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm. Res.21(12), 2226–2233 (2004).
   PubMed Web of Science ®Google Scholar
• Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, Sugiyama T. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug Metab. Dispos.35(7), 1142–1148 (2007).
   PubMed Web of Science ®Google Scholar
• Buhleier E, Wehner W, Vögtle F. ‘Cascade’- and ‘nonskid-chain-like’ syntheses of molecular cavity topologies. Synthesis1978, 155–158 (1978).
   Google Scholar
• Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today10(1), 35–43 (2005).
   PubMed Web of Science ®Google Scholar
• Dufes C, Uchegbu IF, Schatzlein AG. Dendrimers in gene delivery. Adv. Drug Deliv. Rev.57(15), 2177–2202 (2005).
   PubMed Web of Science ®Google Scholar
• Venditto VJ, Regino CA, Brechbiel MW. PAMAM dendrimer based macromolecules as improved contrast agents. Mol. Pharm.2(4), 302–311 (2005).
   PubMedGoogle Scholar
• Bernkop-Schnürch A. Thiomers: a new generation of mucoadhesive polymers. Adv. Drug Deliv. Rev.57(11), 1569–1582 (2004).
   Web of Science ®Google Scholar
• Bromberg L, Alakhov V. Effects of polyether-modified poly(acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J. Control. Release88, 11–22 (2003).
   PubMed Web of Science ®Google Scholar
• Werle M, Hoffer M. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J. Control. Release111(1–2), 41–46 (2006).
   PubMed Web of Science ®Google Scholar
• Föger F, Schmitz T, Bernkop-Schnürch A. in vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials27(23), 4250–4255 (2006).
   PubMed Web of Science ®Google Scholar
• Föger F, Kafedjiiski K, Hoyer H, Loretz B, Bernkop-Schnürch A. Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan. J. Drug Targ.15(2), 132–139 (2006).
   Web of Science ®Google Scholar
• Föger F, Malaivijtnond S, Thanakul W, Huck C, Bernkop-Schnürch A, Werle M. Effect of a thiolated polymer on oral paclitaxel absorption and tumor growth in rats. J. Drug Targ.16(2), 149–155 (2008).
   PubMed Web of Science ®Google Scholar
• Grabovac V, Bernkop-Schnürch A. Thiolated polymers as effective inhibitors of intestinal Mrp2 efflux pump transporters. Sci. Pharm.74(2), 75 (2006).
   Google Scholar
• Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc. Natl Acad. Sci. USA94, 10594–10599 (1997).
   PubMed Web of Science ®Google Scholar
• Pascaud C, Garrigos M, Orlowski S. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem. J.333, 351–358 (1998).
   PubMed Web of Science ®Google Scholar
• Shapiro AB, Fox K, Lam P, Ling V. Stimulation of P-glycoprotein mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur. J. Biochem.259, 841–850 (1999).
   PubMedGoogle Scholar
• Lugo MR, Sharom FJ. Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site. Biochemistry44, 643–655 (2005).
   PubMed Web of Science ®Google Scholar
• Loo TW, Clarke DM. Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J. Biol. Chem.277, 44332–44338 (2002).
   PubMed Web of Science ®Google Scholar
• Loo TW, Bartlett MC, Clarke DM. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. J. Biol. Chem.278, 13603–13606 (2003).
   PubMed Web of Science ®Google Scholar
• Crivori P, Reinach B, Pezzetta D, Poggesi I. Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol. Pharm.3(1), 33–44 (2006).
   PubMed Web of Science ®Google Scholar
• Shilling RA, Venter H, Velamakanni S et al. New light on multidrug binding by an ATP-binding-cassette transporter. Trends Pharmacol. Sci.27(4), 195–203 (2006).
   PubMed Web of Science ®Google Scholar
• Ekins S, Kim RB, Leake BF et al. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol. Pharm. Pharmacol.61(5), 964–973 (2002).
   PubMed Web of Science ®Google Scholar
• Wigler PW, Patterson FK. Reversal agent inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochim. Biophys. Acta1189(1), 1–6 (1994).
   PubMed Web of Science ®Google Scholar
• Kodawara T, Masuda S, Wakasugi H et al. Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. Pharm. Res.19(6), 738–743 (2002).
   PubMed Web of Science ®Google Scholar
• Baluom M, Friedman DI, Rubinstein A. Absorption enhancement of calcitonin in the rat intestine by carbopol-containing submicron emulsions. Int. J. Pharm.154, 235–243 (1997).
   Web of Science ®Google Scholar
• Perloff MD, Stormer E, von Moltke LL, Greenblatt DJ. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm. Res.20(8), 1177–1183 (2003).
   PubMed Web of Science ®Google Scholar
• Höllt V, Kouba M, Dietel M, Vogt G. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem. Pharmacol.43(12), 2601–2608 (1992).
   PubMed Web of Science ®Google Scholar
• Barancik M, Polekova L, Mrazova T, Breier A, Stankovicova T, Slezak J. Reversal effects of several Ca(2+)-entry blockers, neuroleptics and local anaesthetics on P-glycoprotein-mediated vincristine resistance of L1210/VCR mouse leukaemic cell line. Drugs Exp. Clin. Res.20(1), 13–18 (1994).
   PubMedGoogle Scholar
• Wandel C, Kim RB, Guengerich FP, Wood AJ. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab. Dispos.28(8), 895–898 (2000).
   PubMed Web of Science ®Google Scholar
• Aebi S, Schnider TW, Los G et al. A Phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemother. Pharmacol.44(3), 259–265 (1999).
   PubMed Web of Science ®Google Scholar
• Gruol DJ, Bourgeois S. Expression of the mdr1 P-glycoprotein gene: a mechanism of escape from glucocorticoid-induced apoptosis. Biochem. Cell Biol.72(11–12), 561–571 (1994).
   PubMed Web of Science ®Google Scholar
• Kirk J, Syed SK, Harris AL et al. Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives. Biochem. Pharmacol.48(2), 277–285 (1994).
   PubMed Web of Science ®Google Scholar
• Peck RA, Hewett J, Harding MW et al. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J. Clin. Oncol.19(12), 3130–3141 (2001).
   PubMed Web of Science ®Google Scholar
• Kimura Y, Aoki J, Kohno M, Ooka H, Tsuruo T, Nakanishi O. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother. Pharmacol.49(4), 322–328 (2002).
   PubMed Web of Science ®Google Scholar
• Walker J, Martin C, Callaghan R. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur. J. Cancer40(4), 594–605 (2004).
   PubMed Web of Science ®Google Scholar
• Hugger ED, Cole CJ, Raub TJ, Burton PS, Borchardt RT. Automated analysis of polyethylene glycol-induced inhibition of P-glycoprotein activity in vitro. J. Pharm. Sci.92(1), 21–26 (2003).
   PubMed Web of Science ®Google Scholar
• Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by d-a-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res.16(10), 1550–1556 (1999).
   PubMed Web of Science ®Google Scholar